Drugmaker AstraZeneca announced on Monday that its experimental coronavirus vaccine has shown an average efficacy of 70% in its large scale trials -- the latest of several vaccine trials worldwide to post their results this month.
The vaccine, developed with the University of Oxford, showed 90% efficacy in one dosing regimen, and 62% efficacy in a second regimen. That averages to a 70% efficacy, AstraZeneca said.
The company said in a news release that its vaccine was “highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine."
The interim analysis included a total of 131 Covid-19 cases, according to the release.
Other vaccines in the works: This comes after Moderna announced earlier this month that its vaccine was 94.5% effective against coronavirus, and Pfizer announced its vaccine was 95% effective.